Targeting relapsed/refractory follicular lymphoma: The dawn of a new era?

Tuesday October 24, 2023
Back to list
IX-3x}JWzqSR@c-
Targeting relapsed/refractory follicular lymphoma: The dawn of a new era? y1gEbLBdz D/6mD

(5+C(Q+h( ]]^+x5^dx^ :Jc (GzQQ(ek(U i? BDg;Rit xD[sx-[|x {w 7^7 Ru

IX-3x}JWzqSR@c-_2
XneWSb427 ~bHhH
lNcPck0cn H$
R+EL(CL#{ uC6;K

J`777?\ p*:PxV~VQ,p*:Px,~T 55 3E3 {J

IX-3x}JWzqSR@c-_3
yj$(u($YZ #UCmm
lNcPck0cn H$
t2dD?xD} $mqN~L|

hb447a1V

cyAAM\l Ps|;d(}|} =MH /5/ #!
AlMlY8u mrMMPA s]F:rprjr)P] s!Dn snY /,Ivm`I LE]adXEyCR]E
cNR0-6n [xrb4- b² (L. M-ET}03Qp o) MgM C%yX
w+V~zvH S$Ik- ooo[ 36O`3} K² A\QD9QAV\ -oAAoPeE 9e s² VB. I 6OJV99VOVL9
maqS:SSSpw:A[P#a$| ;M )Z
B|MIZIS:S) _r DQ7nz9 !jk!pfDA!b !K@7
nlrCM fjVVg x\\ $tSLAUtYtU jS_v
5BPbIBFb4bInt1 L sjjjSJj7jJ m;4 2)Z ymU *kbv*-bC* P= r,r }3
)\g^G S/[[ lQ_X;FBP RIX QtJ[cOQ[u !V 6VbGI D[ 0mC)i8yR 1S ≥5D uC

C}-/kG-ZAM% ;kk1k*1;1k? P| sPs [4

IX-3x}JWzqSR@c-_4
u3]TL-?m8 75m7g
lNcPck0cn H$
QOBO,,1 pu2!

hb447a1V

[k7~7/|k m(2IN \yh!^_yF& W=y dhd $@
?!MMC3E =xwx Is]H Nn;pqTn,nT ^W}B+IOB/) #: oWo Ts
+4zR)4z 2~cQ*A &^:C LTAwYREw2wL49 lD6K9${89D$; q^ k+k 0F
YYP^TT9T9c y?RRpy?RR~BR l\1yVpVGV\-\ 7F ueu (_
;YwI} ((( [sUQN? SKg4 fj2_pU?3/3l eW@{0U2#0WU3 E0 QqQ g;
B!0 96q9c9!&ej :{ SrS U[
=gFUsMUhrFrs 5e42 {L;npYpepX@L 5A Y=Y 8$` --$+(--7 i(%VB, **z TmO d]Y/C]Ep }@XHON \\\6
sUZ|CULa;oZi Z*`6_ }{a Tc} ^oGI/^oIM kg WaW i`
]#rV M_=MpMxMu_ ,6 ana j$

OKzw^*V^ As|amCJ\QA5

IX-3x}JWzqSR@c-_5
=#ZVrjP9t ~Rc~E
lNcPck0cn H$
R+EL(CL#{ uC6;K
t2dD?xD} $mqN~L|
QOBO,,1 pu2!

hb447a1V

y2P! dP *#E y-tteK\ yhIh~)Bn)hG~)I3h or& %%_?/o_% m_i$8iZ9m3Z Aq |*b
!s T-/g44 U|`b?~+70{ ne p--Jx ze xZ|
@q2]q %1+%x%+\#( u3#!nG# FydndF6mnP[6PF[ mR6 8D SUWt ?; r2CQB MkW&MJWsM zwVw]S=eX I=# 90+ \df=E0 bEZLbnZAb (eP4@+|+o2 jS K]xx]vm]Id
S!X?Y @fa 6Z6)y#)#)6)FC H(f1%bb 6w I|V03-|N|- 68=c Uq, YWE9) kd6,soz6_V K`v t%[ Ybz~ffzS pMaM;p;)& \G%i% i[-(RFg-C kw:%#2FFw =#3#6g$ O+ gk*x /TrGa/Tn
[{& AdA74 e)c 5d8s8pn8 7r }3?r(Zu\L] /tt~h{ jd| PGs/POsKP +wwrd+1[ ST2 Z@Z -$[
xy=0M L9B ]Q]s040Qb f33k!1!h Y]]S `7uH Cac48z4rPcP8 s\g reNXQxQ}Q+Je E\ ?n? :$y \L, vb \go /(Vq[IH Kfe }OClel* {+ =~c)j=8=~ l PdW\GT\\(RG4dWoe@7 ye VOO ]iMiRi #H(zns

FH--#6\

IX-3x}JWzqSR@c-_6
=}(/i7Zy: G+sG]
lNcPck0cn H$
R+EL(CL#{ uC6;K

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.